Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren vs Enalapril in C3 Glomerulopathy
NCT04183101Phase 2Recruiting
- Sponsor
- Region Skåne
- Start
- Oct 2020
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aliskiren in Complement 3 glomerulopathy (C3G) (2 arms), sponsored by Region Skåne. Primary endpoints: C3 levels in serum at 3 years and Complement deposition in kidneys at 3 years. Started Oct 2020; status: recruiting.
02
Drugs
aliskiren
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT04183101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183101.